Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
View Patent ↗The invention relates to novel nucleic acids encoding a mammalian PCADM-1 gene, and proteins encoded thereby, whose expression is increased in certain diseases, disorders, or conditions, including, but not limited to, prostate cancer. The invention further relates to methods of detecting and treating prostate cancer, comprising modulating or detecting PCADM-1 expression and/or production and activity of PCADM-1 polypeptide. Further, the invention relates to novel assays for the identification of DNA-binding proteins and the double-stranded oligonucleotide sequences that specifically bind with them. Finally, the invention relates to DNAZYMs or DNA enzymes which specifically bind PCADM-1 mRNA to inhibit PCADM-1 gene expression and thereby destroy tumor cells and tumor tissue.
1. An isolated antibody that specifically binds with a mammalian prostate cancer antigen diagnostic marker 1 polypeptide wherein said mammalian prostate cancer antigen diagnostic marker 1 polypeptide comprises SEQ ID NO:2, and wherein said antibody does not crossreact non-specifically with human S2 40S ribosomal protein.
2. The antibody of claim 1 , wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a humanized antibody, a chimeric antibody, and a synthetic antibody.
3. A composition comprising an isolated antibody that specifically binds with a mammalian prostate cancer antigen diagnostic marker 1 polypeptide and a pharmaceutically-acceptable carrier, wherein said mammalian prostate cancer antigen diagnostic marker 1 polypeptide comprises SEQ ID NO:2, and wherein said antibody does not crossreact non-specifically with human S2 40S ribosomal protein.